Hill-Rom Holdings (NYSE:HRC) said it will lay off about 3% of its workforce, or roughly 200 workers, as it maneuvers to confront the medical device tax set to go into effect next year.
Neurometrix
Will Intuitive Surgical’s stock ever stop? | Wall Street Beat
Shares of Intuitive Surgical (NSDQ:ISRG) hit an all-time high yesterday of $529.70 and beat it today, as investors sent the shares to $531.35 apiece this morning.
The spikes followed an upgrade by analysts at Lazard Capital, who raised their price target on the stock to $575 from $525 and reinforced their “buy” rating.
Olympus board resigns en masse | Wall Street Beat
The new slate of directors for Olympus Corp. (TYO:7733) is already drawing fire from foreign investors in the endoscopy giant, after its entire board resigned en masse over a $1.7 billion accounting scandal that’s slashed its valuation by about 50% since October.
Masimo meets The Street, shares rise | Earnings Roundup
Masimo (NSDQ:MASI) met Wall Street’s forecast for its full-year and 4th-quarter earnings, giving its shares a 2% bump yesterday and sending them another 3% higher today.
The Irvine, Calif.-based patient monitoring systems maker reported profits of $$13.8 million, or 23 cents per share, on sales of $112.3 million for the 3 months ended Dec. 31, 2011, for a top-line increase of 6.4% but a bottom-line decline of 14.2%, compared with Q4 2010.
AngioDynamics details $372M Navilyst buyout details | Wall Street Beat
Financial projections from AngioDynamics (NSDQ:ANGO) about its $372 million deal to acquire Navilyst Medical show that it expects to reap some significant rewards from the merger over the short and long terms.
Acquisition chatter surfaces again for Smith & Nephew
Shares of Smith & Nephew (NYSE:SNN) slipped initially but have regained some of their value since more talk of a possible buyout surfaced in the U.K. last week.
The British orthopedics giant is up 2.7 percent on The Street today to $43.94 after flirting with a 52-week low Friday, Nov. 25. The stock has fared even worse in its home country following an "uninspiring" meeting with analysts last week.
Zimmer slides despite beating The Street | Earnings Roundup
Zimmer Holdings (NYSE:ZMH) shares are down this morning in early trading after the orthopedics giant lowered its sales and earnings guidance for 2011 – despite beating analysts’ expectations with its third-quarter earnings.
Warsaw, Ind.-based Zimmer said third-quarter profits were $192 million, or $1.01 per share, on sales of $1.03 billion for the three months ended Sept. 30, up 5.2 percent and 6.9 percent, respectively, compared with the same period last year.
ACT appoints MIT big shot Langer to board | Personnel Moves
Advanced Cell Technology (OTC:ACTC) appointed MIT professor and bioengineering legend Bob Langer to its board of directors, tapping him to lead its science advisory committee.
Langer has authored more than 1,100 journal articles, has more than 800 issued and pending patents and won the 2011 Warren Alpert Foundation Prize for bioengineering pioneers thanks to his work in drug delivery and tissue engineering.
NeuroMetrix Names Kenneth J. Snow, M.D. as Chief Medical Officer
WALTHAM, Mass.–(BUSINESS WIRE)–NeuroMetrix, Inc. (Nasdaq: NURO) today announced the appointment of Kenneth J. Snow, M.D. as Chief Medical Officer. The appointment was effective October 3, 2011.
“His intellect, natural curiosity, and experience will be invaluable as he leads our diabetes focused clinical programs.”
As Chief Medical Officer, Dr. Snow will be responsible for developing and managing the Company’s diabetes related clinical programs. These include studies to further validate the clinical and economic benefits of NC-stat® DPNCheck™ testing and various clinical and R&D activities in support of new diabetic neuropathy focused products in early development
NeuroMetrix back in NASDAQ’s good graces, hits diabetes market with new test
A 1-for-6 reverse stock split worked out for NeuroMetrix Inc. (NSDQ:NUROD), which said today that it’s back in the good graces of the NASDAQ exchange, and announced a new product launch for the diabetes market.
The Waltham, Mass.-based company, a former high flier on Wall Street, has fallen back to earth after hitting a high-water mark of $39.35 per share in August 2006.
Diabetes device mass infections worry CDC, Neurometrix reverse splits stock, St. Jude Medical goes to court | MassDevice.com +3
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with Massdevice +3.